NOVELION THERAPEUTICS INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - CAD | -.--% |
|
-2.92% | -.--% |
| 2020 | Novelion Therapeutics Inc. Announces Management Changes | CI |
| 2020 | Novelion Therapeutics Inc. Announces Management Changes | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2017 | 138.44 188.6 11.55K | Sales 2018 | 130.43 177.69 10.88K | Capitalization | 15.9M 21.66M 1.33B |
|---|---|---|---|---|---|
| Net income 2017 | -127M -173M -10.6B | Net income 2018 | -108M -147M -9.01B | EV / Sales 2017 | 18,87,512 x |
| Net Debt 2017 | 203M 277M 16.95B | Net Debt 2018 | 303M 413M 25.31B | EV / Sales 2018 | 24,47,567 x |
| P/E ratio 2017 |
-0.46
x | P/E ratio 2018 |
-0.15
x | Employees | - |
| Yield 2017 * |
-
| Yield 2018 |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
More press releases
Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The Company holds a portfolio of products through its subsidiary, Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company's portfolio of products include MYALEPT and JUXTAPID. The Company is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.
Sector
-
- Stock Market
- Equities
- NVLNF Stock
- NVLN Stock